Three-dimensional scatter plot analysis to estimate the risk of foetal aneuloidy: A further development of first trimester screening;Dreidimensionale Scatterplotanayse zur Risikoeinschätzung für fetale Aneuploidien: Eine Weiterentwicklung des Ersttrimester-Screenings

Zeitschrift fur Geburtshilfe und Neonatologie

Volumn 212, Issue 4, 2008, Pages 127-135

  Schmidt, Peter ^a   Hormansdorfer C ^a   Oehler, K ^a   Harterl H ^a   Hillemanns, P ^a   Scharf, A ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

First trimester screening; Nuchal translucency; Risk calculation; Trisomy 21

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ALGORITHM; ANEUPLOIDY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FEASIBILITY STUDY; FETUS; FETUS DISEASE; FIRST TRIMESTER PREGNANCY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL DIAGNOSIS; PRENATAL SCREENING; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; BLOOD; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER GRAPHICS; EVALUATION; FEMALE; GENETIC SCREENING; GENETICS; GERMANY; METHODOLOGY; MULTICENTER STUDY; PREGNANCY; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICS;

ALGORITHMS; ANEUPLOIDY; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CHROMOSOME ABERRATIONS; COMPUTER GRAPHICS; DATA INTERPRETATION, STATISTICAL; DIAGNOSIS, COMPUTER-ASSISTED; FEMALE; FETAL DISEASES; GENETIC SCREENING; GERMANY; HUMANS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 52949144148     PISSN: 09482393     EISSN: 14391651     Source Type: Journal    
DOI: 10.1055/s-2008-1004708     Document Type: Article

References (56)

1. Down L. Observations on an ethnic classification of idiots. Clin Lectures and Reports, London Hospital 1866; 3: 259-262
2. Lejeune J, Gautier M, Turpin R. Etudes des chromosomes somatiques de neuf enfants mongoliens. C R Acad Sci 1959; 248: 1721
3. Shuttleworth GE. Mongolian imbecility. Br Med J 1909; 2: 661-665
4. Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über die ärztliche Betreuung während der Schwangerschaft und nach der Entbindung ("Mutterschafts-Richtlinien") in der Fassung vom 10. Dezember 1985. (veröffentlicht im Bundesanzeiger Nr. 60a vom 27. März 1986) zuletzt geändert am 28. Oktober 2002 (veröffentlicht im Bundesanzeiger Nr. 242 vom 31.12.2002) in Kraft getreten am 1.Januar 2003. Bundesanzeiger Nr. 242 2002 (73. Ergänzungslieferung)
5. Schmidt P, Hörmansdörfer C, Staboulidou I, Seydel J, Vaske B, Brocker K, Hillemanns P. Gesundheitsökonomische Aspekte des Downsyndrom-Screenings: Vergleich der Mutterschaftsrichtlinien mit aktuellen Algorithmen zur Risikoberechnung. Geburtsh Frauenheilk 2008; 68: 67-76
6. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff I, Craigo SD, Timor-Tritsch IE, Carr, SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AP, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D'Alton ME. First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353: 2001-2011
7. Wald NJ, Cuckle HS, Densem JW et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988; 297: 883-887
8. Cheng EY, Luthy DA, Zebelman AM, Williams MA, Lieppman RE, Hickok DE. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. Obstet Gynecol 1993; 81: 72-77
9. Goodburn SF, Yates JR, Raggatt PR et al. Second-trimester matemal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: experience of a regional programme. Prenat Diagn 1994; 14: 391-402
10. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. Br Med J 1992; 304: 867-889
11. Krampl E, Wertaschnigg D, Husslein P. Down-Syndrom-Screening im ersten Trimenon. Geburtshilfe Frauenheilk 2002; 62: 843-848
12. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, Platt L, Mahoney M, Johnson A Hogge WA, Wilson RD, Mohide P, Hershey D, Krantz D, Zachary J, Snijders R, Greene N, Sabbagha R, MacGregor S, Hill I, Gagnon A, Hallahan T, Jackson L. First-trimester screening for trisomy-21 and 18. N Engl J Med 2003; 349: 1405-1413
13. Nicolaides KH, Sebire N, Snijders RJM. Die Ultraschalluntersuchung der 11-14.Schwangerschaftswoche. Birmingham, Pathenon Publishing, 1999
14. Palomaki GE, Haddow JE. Maternal serum alpha-fetoprotein, age, and Down syndrome risk. Am J Obstet Gynecol 1987; 156: 460-463
15. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynecol 2002; 20: 219-225
16. Bieniakiewicz I, Brunk J, Lammers C, Gembruch U, Kowalcek I. Die aktuelle Beanspruchung werdender Eltern vor und nach pränataler Diagnostik in Abhängigkeit von der Untersuchungsindikation. Geburtsh Frauenheilk 2006; 66: 566-574
17. Steele MW, Breg Jr WR. Chromosome analysis of human amniotic-fluid cells. Lancet 1966; 1: 383-385
18. Tabor A Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986; 1: 1287-1293
19. Benz R, Muller U, Krahner-Pilat M, Wagner-Geuder S, Terinde R. Serum-Screening auf Down-Syndrom bei Frauen unter 35 Jahren mit einem altersunabhängigen Inde. Z Geburtshilfe Perinatol 1993; 197: 205-208
20. Nicolaides KH, Brizot ML, Patel F, Snijders RJM. Comparison of chorionic villus sampling and amniocentesis for fetal karyotyping at 10-13 weeks' gestation. Lancet 1994; 344: 435-439
21. Sundberg K, Bang J, Smidt-Jensen S. Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. Lancet 1997; 350: 697-703
22. Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y, Porter TF, Luthy DA, Comstock CH, Saade GR, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006; 108: 1067-1072
23. Schmidt P, Scharf A. Advanced Firsthimester Screening - A critical review of the fundamental studies and suggestions for improvement. Geburtsh Frauenheilk 2006: 67: S1-S183
24. Schmidt P, Rom J, Maul H, Vaske B, Hillemanns P, Scharf A. Advanced First Trimester Screening (AFS) - An improved test strategy for the individual risk assessment of fetal aneuploidies and malformations. Arch Gynecol Obstet 2007: 276: 159-166
25. Hörmansdörfer C, Schmidt P, Hillemanns P, Scharf A. Die pränatale Detektion der Trisomien 13,18 und 21: Vergleich des Advanced First Trimester Screenings (AFS)® mit dem Ersttrimesterscreening nach Nicolaides. Z Geburtsh Neonatol 2007: 211: 243-249
26. Herman A, Maymon R, Dreazen E, Caspi E, Bukovsky I, Weinraub Z. Nuchal translucency audit: a novel image-scoring method. Ultrasound Obstet Gynecol 1998; 12: 398-403
27. Merz E. 11 - 14 SSW Screening - Zertifizierte Ultraschalluntersuchung und zertifizierter biochemischer Test in der Frühgravidität. Ultraschall in Med 2002; 23: 161-162
28. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 1998: 351: 343-346
29. Nicolaides KH. First-trimester screening for chromosomal abnormalities. Semin Perinatol 2005; 29: 190-194
30. Falcon O, Faiola S, Huggon I, Allan L, Nicolaides KH. Fetal tricuspid regurgitation at the 11 + 0 to 13 + 6-week scan: association with chromosomal defects and reproducibility of the method. Ultrasound Obstet Gynecol 2006; 27: 609-612
31. Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides KH. Absence of nasal bone in fetuses with trisomy 21 at 11 - 14 weeks of gestation: an observational study. Lancet 2001; 358: 1665-1667
32. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG 2000; 107: 1271-1275
33. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003; 110: 281-286
34. Kozlowski P, Knippel AJ, Froehlich S, Stressig R. Additional performance of nasal bone in first trimester screening. Ultraschall in Med 2006; 27: 336-339
35. Schmidt P, Staboulidou I, Sohn C. Das Nasenbein im Ersttrimester-Screening. Frauenarzt 2005; 8: 664-665
36. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997; 17: 821
37. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221-226
38. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353: 2001-2011
39. OLeary P, Breheny N, Dickinson JE, Bower C, Goldblatt J, Hewitt B et al. First-trimester combined screening for Down syndrome and other fetal anomalies. Obstet Gynecol 2006; 107: 869-876
40. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. BJOG 2002; 109: 667-676
41. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynecol 2002; 20: 219-225
42. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003; 110: 281-286
43. Hadlow NC, Hewitt BG, Dickinson JE, Jacoby P, Bower C. Community-based screening for Down's Syndrome in the first trimester using ultrasound and maternal serum biochemistry. BJOG 2005; 112: 1561-1564
44. Wapner R, Thom E, Simpson JL et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003; 349: 1405-1413
45. Wojdemann KR, Shalmi AC, Christiansen M et al. Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women. Ultrasound Obstet Gynecol 2005; 25: 227-233
46. Muller F, Benattar C, Audibert F, Roussel N, Dreux S, Cuckle H. First-trimester screening for Down syndrome in France combining fetal nuchal translucy measurement and biochemical markers. Prenat Diagn 2003; 23: 833-836
47. Stenhouse EJ, Crossley JA, Aitken DA, Brogan K, Cameron AD, Connor JM. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Prenat Diagn 2004; 24: 774-780
48. Schuchter K, Hafner E, Stangl G, Metzenbauer M, Hofinger D, Philipp K. The first trimester 'combined test' for the detection of Down syndrome pregnancies in 4939 unselected pregnancies. Prenat Diagn 2002; 22: 211-215
49. Perni SC, Predanic M, Kalish RB, Chervenak FA, Chosen ST. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Am J Obstet Gynecol 2006; 194: 127-130
50. Schielen PC, van Leeuwen-Spruijt M, Belmouden I, Elvers LH, Jonker M, Loeber JG. Multi-centre first-trimester screening for Down syndrome in the Netherlands in routine clinical practice. Prenat Diagn 2006: 26: 711-718
51. Kaisenberg CS von, Gasiorek-Wiens A, Bielicki M, Bahlmann F, Meyberg H, Kossakiewicz A et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study. J Matern Fetal Neonatal Med 2002; 12: 89-94
52. Soergel P, Pruggmayer M, Schwerdtfeger R, Mühlhaus K, Scharf A. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: A regional experience from germany. Fetal Diagn Ther 2006; 21: 264-268
53. Scott F, Peters H, Bonifacio M et al. Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population. Aust N Z J Obstet Gynaecol 2004; 44: 205-209
54. Schmidt P, Staboulidou I, Soergel P, Wilstemann M, Hillemanns P, Scharf A. Comparison of Nicolaides' risk evaluation for Down's syndrome with a novel software: An analysis of 1463 cases. Arch Gynecol Obstet 2007; 275: 469-474
55. Scharf A, Schmidt P, Seppelt M, Maul H, Wilstermann M, Sohn C. Vergleich der Risikokalkulation für Trisomie 21 nach Nicolaides mit einer neu entwickelten Software: Retrospektive Analyse an 744 Fällen. Geburthilfe Frauenheilkd 2003; 63: 148-152
56. Schmidt P, Pruggmayer M, Steinborn A, Schippert C, Staboulidou I, Hillemanns P, Scharf A. Are nuchal translucency, pregnancy associated plasma protein-A or free-β-human chorionic gonadotropin depending on maternal age? A multicenter study of 8116 pregnancies. Arch Obstet Gynecol 2007: 276: 259-262